Rampart Bioscience, Inc.

About Rampart Bioscience, Inc.

Rampart Bioscience is a biotechnology company focused on developing a new class of non-viral gene medicines for patients with genetically driven diseases. Their mission is to provide safe, long-lasting treatments using a proprietary DNA delivery system, aiming for higher potency, durability, redosability, and safety to reshape treatment options for those in need.

Products & Services

Non-Viral DNA-Based Medicines:A novel class of gene therapies using a non-viral DNA delivery system designed for enhanced potency, durability, redosability, and safety.

Therapeutics for Genetic Diseases:Optimized therapeutics targeting inherited metabolic disorders and other high-need genetic diseases through proprietary development and delivery platforms.

Specialties

Gene Therapy Non-Viral DNA Delivery Genetic Disease Treatment Biotherapeutic Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 85000000 MR: - FA: $85 million FAN: 85000000	D: 2023-10-24 FD: 2023-10-24	4 investors

Series A Latest

2023-10-24

$85.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Anderson

L

Louis Breton

CEO, Co-founder

J

Jeffrey Bartlett

Chief Innovation and Technical Officer

D

David Baltimore

Nobel Laureate

View 1 more team members with Pro

Unlock Full Team Directory

Recent News